Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics develops targeted protein degradation medicines for immunological diseases as a clinical-stage biopharmaceutical company. News about KYMR commonly centers on oral small molecule degrader programs, including KT-621, a STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and asthma, and KT-579, an IRF5 degrader tied to inflammatory bowel disease biology.
Company updates also cover preclinical and clinical data presentations, FDA regulatory designations, collaboration activity involving degrader candidates such as KT-200, and periodic operating and financial results. Additional announcements include investor conference participation and shareholder voting matters.
Kymera Therapeutics (NASDAQ: KYMR) announced new Phase 1 data for KT-333, a STAT3 degrader, set to be presented at the European Hematology Association (EHA) Annual Meeting from June 13-16, 2024. The data cut-off date was February 6, 2024. The ongoing study involves 39 patients with various hematologic and solid tumors. Key highlights include two complete responses in classic Hodgkin's lymphoma patients, three partial responses in cutaneous T-cell lymphoma patients, and stable disease in four solid tumor patients. KT-333 achieved a maximum degradation of 97.5% in peripheral blood mononuclear cells, showing favorable immunomodulatory responses. The drug was generally well-tolerated, though two dose-limiting toxicities were observed. Kymera plans to share more data in the second half of 2024.
Kymera Therapeutics, a clinical-stage biopharmaceutical company, will participate in investor conferences in May 2024. They will be attending events like the BofA Securities 2024 Health Care Conference and the TD Cowen 5th Annual Oncology Innovation Virtual Summit. The Company aims to showcase its progress in developing small molecule medicines through targeted protein degradation (TPD).
Kymera Therapeutics, Inc. announced its first quarter 2024 financial results, reporting $745 million in cash. The company is advancing various clinical-stage programs with data expected in 2025. Business updates include expanding the pipeline with a focus on immunology, unveiling oral degrader programs for STAT6 and TYK2, and ongoing Phase 1 studies for MDM2 and STAT3 inhibitors. Kymera remains well-capitalized and has extended its cash runway into 2027.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.